The Chikungunya Fever drugs in development market research report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chikungunya Fever. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued products.

GlobalData tracks 53 drugs in development for Chikungunya Fever by 47 companies/universities/institutes. The top development phase for Chikungunya Fever is preclinical with 31 drugs in that stage. The Chikungunya Fever pipeline has 39 drugs in development by companies and 14 by universities/ institutes. Some of the companies in the Chikungunya Fever pipeline products market are: Meletios Therapeutics, University of Oxford and Sementis.

The key targets in the Chikungunya Fever pipeline products market include Chikungunya Virus E2 Protein (Envelope Glycoprotein E2 or Spike Glycoprotein E2 or E2), Chikungunya Virus E1 Protein (Envelope Glycoprotein E1 or Spike Glycoprotein E1 or E1), and Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80).

The key mechanisms of action in the Chikungunya Fever pipeline product include Chikungunya Virus E2 Protein (Envelope Glycoprotein E2 or Spike Glycoprotein E2 or E2) Inhibitor with three drugs in Phase I. The Chikungunya Fever pipeline products include seven routes of administration with the top ROA being Intramuscular and 12 key molecule types in the Chikungunya Fever pipeline products market including Recombinant Vector Vaccine, and Monoclonal Antibody.

Chikungunya Fever overview

Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting, and rash and fever. Treatment includes use of non-steroidal anti-inflammatory drugs (NSAIDs).

For a complete picture of Chikungunya Fever’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.